AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24470004 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of 90-minute twice per week hatha yoga classes
Number of subjects: 200
Study 24470004 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 200
Study 24470398 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD patients
Number of subjects: 70
Study 24470398 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD diagnosis
Number of subjects: 70
Study 24470559 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Number of subjects: 254
Study 24471561 — intervention group
Group type: EXPERIMENTAL
Intervention: zone-model predictive control (zone-MPC) with health monitoring system (HMS)
Number of subjects: 12
Study 24471651 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Number of subjects: 194
Study 24472814 — intervention group
Group type: EXPERIMENTAL
Intervention: High MDR1 transcript levels
Number of subjects: 0
Study 24472814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR-ABL(IS) <28%
Number of subjects: 0
Study 24472814 — intervention group
Group type: EXPERIMENTAL
Intervention: No mutation
Number of subjects: 0
Study 24472814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study 24473178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy with assessment of collateral grade
Number of subjects: 331
Study 24473178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy with robust angiographic collateral grade
Number of subjects: 331
Study 24473509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive treatment (tenecteplase thrombolysis followed by percutaneous coronary intervention)
Number of subjects: 398
Study 24473509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 398
Study 24473509 — intervention group
Group type: COMPARATOR
Intervention: Successful thrombolysis
Number of subjects: 398
Study 24473509 — intervention group
Group type: COMPARATOR
Intervention: Final myocardial blush grade 3
Number of subjects: 398
Study 24473509 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Registry of Acute Coronary Events score
Number of subjects: 398
Study 24473509 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 398
Study 24473509 — intervention group
Group type: EXPERIMENTAL
Intervention: Final myocardial blush grade of 0-2
Number of subjects: 398
Study 24474568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day) with non-ritonavir HAART
Number of subjects: 19
Study 24474568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (dose escalation from 25 mg/day to 50 mg/day) with ritonavir-based HAART
Number of subjects: 19
Study 24475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial T1 values in diastole
Number of subjects: 40
Study 24475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial T1 values in systole
Number of subjects: 40
Study 24475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-normalized myocardial T1 values
Number of subjects: 40
Study 24475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of blood T1 with segmental myocardial T1
Number of subjects: 40
Study 24475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-normalized diastolic and systolic myocardial T1 values
Number of subjects: 40
Study 24475922 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg once daily for 8 weeks)
Number of subjects: 40
Study 24476740 — intervention group
Group type: EXPERIMENTAL
Intervention: Progenitor cell therapy (CD34+ selected cell suspension injected into the wound)
Number of subjects: 3
Study 24476740 — intervention group
Group type: COMPARATOR
Intervention: Sham side (no progenitor cell treatment)
Number of subjects: 3
Study 24476740 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic analysis after progenitor cell treatment
Number of subjects: 3
Study 24477040 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC program feeding practices
Number of subjects: 4000
Study 24477040 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative 24-h recall of food intake for the infant
Number of subjects: 4000
Study 24477042 — intervention group
Group type: EXPERIMENTAL
Intervention: GCKR rs780094 TT genotype
Number of subjects: 797
Study 24477042 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 variant
Number of subjects: 797
Study 24477042 — intervention group
Group type: COMPARATOR
Intervention: NCAN, LYPLAL1, PPP1R3B variants
Number of subjects: 797
Study 24477328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (500 mg, once daily for 2-5 days) followed by oral azithromycin (500 mg, once daily for 7-10 days)
Number of subjects: 102
Study 24477368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy
Number of subjects: 93
Study 24477369 — intervention group
Group type: EXPERIMENTAL
Intervention: ScopeGuide (electromagnetic field exposure)
Number of subjects: 100
Study 24477453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate therapy (3-h intravenous infusion aiming to increase systemic lactate to ca. 5 mmol/L)
Number of subjects: 15
Study 24477453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate therapy
Number of subjects: 15
Study 24477603 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5 mg/m2 ombrabulin
Number of subjects: 15
Study 24477603 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/m2 ombrabulin
Number of subjects: 15
Study 24477603 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/m2 ombrabulin
Number of subjects: 15
Study 24477603 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 ombrabulin
Number of subjects: 15
Study 24477603 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 15
Study 24477837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 288
Study 24477837 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 288
Study 24477837 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cognitive Behavioral Therapy and Medication
Number of subjects: 288
Study 24477837 — intervention group
Group type: COMPARATOR
Intervention: Pill Placebo
Number of subjects: 288
Study 24477837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Treatment Responders
Number of subjects: 288
Study 24477837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Treatment Non-Responders
Number of subjects: 288
Study 24478152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 1
Study 24478152 — intervention group
Group type: COMPARATOR
Intervention: Conventional transesophageal echocardiography (TEE)
Number of subjects: 1
Study 24480627 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D <20 ng/ml
Number of subjects: 3002
Study 24480627 — intervention group
Group type: EXPERIMENTAL
Intervention: parathyroid hormone ≥65 pg/ml
Number of subjects: 3002
Study 24480627 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D ≥30 ng/ml
Number of subjects: 3002
Study 24480627 — intervention group
Group type: COMPARATOR
Intervention: parathyroid hormone <33 pg/ml
Number of subjects: 3002
Study 24480783 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Counseling + Usual Care
Number of subjects: 278
Study 24480783 — intervention group
Group type: COMPARATOR
Intervention: e-Info Control + Usual Care
Number of subjects: 278
Study 24480824 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² intravenously, one or two doses)
Number of subjects: 22
Study 24480824 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 22
Study 24480929 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPCs)
Number of subjects: 266
Study 24480997 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NIV)
Number of subjects: 548
Study 24480997 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation
Number of subjects: 548
Study 24481647 — intervention group
Group type: EXPERIMENTAL
Intervention: Upregulation of miR-378
Number of subjects: 0
Study 24481647 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-378 overexpression
Number of subjects: 0
Study 24481647 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-378 silencing
Number of subjects: 0
Study 24481647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical specimens
Number of subjects: 0
Study 24481953 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) of vitamin K antagonist (VKA), aspirin, and clopidogrel
Number of subjects: 914
Study 24481953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 914
Study 24481953 — intervention group
Group type: EXPERIMENTAL
Intervention: VKA plus clopidogrel
Number of subjects: 914
Study 24482099 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 600 μg bid for 15 days
Number of subjects: 7
Study 24484064 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with a mean dose-length product (DLP) of 746 mGy ⋅ cm (effective dose, 11.2 mSv)
Number of subjects: 49903
Study 24484064 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with reduced dose (DLP of 200 mGy ⋅ cm or lower)
Number of subjects: 49903
Study 24484064 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with DLP at 400 mGy ⋅ cm or less
Number of subjects: 49903
Study 24484456 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Involvement/Low Conflict
Number of subjects: 156
Study 24484456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Involvement/Moderate Conflict
Number of subjects: 156
Study 24484456 — intervention group
Group type: EXPERIMENTAL
Intervention: High Involvement/High Conflict
Number of subjects: 156
Study 24484754 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous shunt creation
Number of subjects: 24
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at low AF risk (n=15)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at moderate AF risk (n=40)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at high AF risk (n=23)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed intraatrial fat predicting ARIC AF risk score
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at low AF risk (n=15)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at moderate AF risk (n=40)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at high AF risk (n=23)
Number of subjects: 90
Study 24485635 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted interatrial septum width
Number of subjects: 90
Study 24486266 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR(CT) derived from coronary computed tomography angiography (CTA)
Number of subjects: 254
Study 24486266 — intervention group
Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 254
Study 24486266 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 254
Study 24486275 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 24486275 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24486892 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep repetitive transcranial magnetic stimulation (DTMS) - 20 Hz, 3000 pulses/session for four weeks
Number of subjects: 15
Study 24487484 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 24 mg/m² (maximum 20 mg/dose) every other week up to 120 weeks
Number of subjects: 32
Study 24488022 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-labelled exendin
Number of subjects: 10
Study 24488560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin (2.5 mg/kg/day for 4 doses)
Number of subjects: 27
Study 24488560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Number of subjects: 27
Study 24488560 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell expression profiling
Number of subjects: 27
Study 24488568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 24488798 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin (25 or 50 mg orally twice daily) + all-trans retinoic acid (ATRA) + CLAG chemotherapy
Number of subjects: 10
Study 24489687 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus group (group 1)
Number of subjects: 40
Study 24489687 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects with corneal astigmatism (group 2)
Number of subjects: 40
Study 24490070 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics
Number of subjects: 171
Study 24491033 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1812
Study 24491312 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of cockroaches in any room
Number of subjects: 100
Study 24491312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily vs single-family dwellings
Number of subjects: 100
Study 24491312 — intervention group
Group type: EXPERIMENTAL
Intervention: Home characteristics
Number of subjects: 100
Study 24491362 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass surgery
Number of subjects: 81
Study 24491362 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 81
Study 24491372 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-monitoring of peak cough expiratory flow, oxygen saturation, and respiratory discomfort
Number of subjects: 18
Study 24492296 — intervention group
Group type: EXPERIMENTAL
Intervention: ARGX-110 (defucosylated IgG1 monoclonal antibody)
Number of subjects: 0
Study 24492296 — intervention group
Group type: COMPARATOR
Intervention: Fucosylated version of ARGX-110
Number of subjects: 0
Study 24493150 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 382
Study 24493150 — intervention group
Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 382
Study 24493150 — intervention group
Group type: EXPERIMENTAL
Intervention: W/Ht
Number of subjects: 382
Study 24493157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day p.o.
Number of subjects: 17
Study 24493215 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-Tacro once-daily
Number of subjects: 57
Study 24493215 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice-daily
Number of subjects: 57
Study 24493287 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression signature including IL8 and LAMC2
Number of subjects: 64
Study 24493287 — intervention group
Group type: COMPARATOR
Intervention: IL8 protein measurement
Number of subjects: 64
Study 24493287 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic targeting of Cxcr2 receptor in murine model
Number of subjects: 64
Study 24493333 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots
Number of subjects: 0
Study 24493333 — intervention group
Group type: COMPARATOR
Intervention: Normal hematocrit concentrations (0.30-0.50) and normal spot volume (40-80 μL)
Number of subjects: 0
Study 24493333 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch position at the perimeter of the blood spot
Number of subjects: 0
Study 24493717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice per day for 1 month (cohort A)
Number of subjects: 29
Study 24493717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice per day for an average of 2.3 months (cohort B)
Number of subjects: 29
Study 24493717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 29
Study 24493717 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients and those previously treated with vismodegib)
Number of subjects: 29
Study 24495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic moderate to severe periodontitis
Number of subjects: 44
Study 24495202 — intervention group
Group type: COMPARATOR
Intervention: Gingivitis and incipient periodontitis
Number of subjects: 44
Study 24495442 — intervention group
Group type: COMPARATOR
Intervention: Before HSCT
Number of subjects: 40
Study 24495442 — intervention group
Group type: EXPERIMENTAL
Intervention: After HSCT
Number of subjects: 40
Study 24495890 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Mental Disorder Questionnaire (CMDQ) anxiety subscale
Number of subjects: 149
Study 24495890 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Mental Disorder Questionnaire (CMDQ) depression subscale
Number of subjects: 149
Study 24495890 — intervention group
Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS) anxiety subscale
Number of subjects: 149
Study 24495890 — intervention group
Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS) depression subscale
Number of subjects: 149
Study 24496231 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated urinary globotriaosylceramide (Gb3) levels in heart disease patients without GLA mutations
Number of subjects: 1408
Study 24496231 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated urinary globotriaosylceramide (Gb3) levels
Number of subjects: 1408
Study 24496231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabry disease patients (n=7)
Number of subjects: 1408
Study 24496231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin and Gb3 levels
Number of subjects: 1408
Study 24496920 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m(2) weekly + cetuximab 250 mg/m(2) weekly + IMRT (70 Gy)
Number of subjects: 25
Study 24496920 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel 80 mg/m(2) weekly + cetuximab + IMRT
Number of subjects: 25
Study 24496920 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m(2) weekly + cetuximab + IMRT
Number of subjects: 25
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: cANCA or pANCA positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3-ANCAs or MPO-ANCAs positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: cANCA/pANCA and PR3-ANCAs/MPO-ANCAs positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid factor (RF) positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANAs) positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (aCL) positivity
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with age
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with echocardiographic vegetations
Number of subjects: 109
Study 24497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with serum IgG levels
Number of subjects: 109
Study 24497573 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless ultrasound-based technology for LV endocardial resynchronization
Number of subjects: 17
Study 24498123 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic extraction of lung vessels from contrast-enhanced thoracic CT scans and calculation of tortuosity using distance metric.
Number of subjects: 24
Study 24498123 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic extraction of lung vessels from contrast-enhanced thoracic CT scans and calculation of 3D fractal dimension.
Number of subjects: 24
Study 24498318 — intervention group
Group type: EXPERIMENTAL
Intervention: OCR 500 mg×2 plus background methotrexate (OCR500+MTX)
Number of subjects: 2759
Study 24498318 — intervention group
Group type: EXPERIMENTAL
Intervention: OCR 200 mg×2 or 400 mg×1 plus background methotrexate (OCR200+MTX)
Number of subjects: 2759
Study 24498318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus background methotrexate (placebo+MTX)
Number of subjects: 2759
Study 24499022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 26
Study 24499022 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26
Study 24499098 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness assessment as cardio-ankle vascular index
Number of subjects: 94
Study 24499098 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function assessment as reactive hyperemia index
Number of subjects: 94
Study 24499098 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE calculation for cardiovascular risk
Number of subjects: 94
Study 24499098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 94
Study 24499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate-adjusted logistic regression
Number of subjects: 0
Study 24499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted logistic regression
Number of subjects: 0
Study 24499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder analysis outcomes
Number of subjects: 0
Study 24499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (mRS)
Number of subjects: 0
Study 24499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichotomized National Institute of Health Stroke Scale (NIHSS)
Number of subjects: 0
Study 24499496 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001
Number of subjects: 4
Study 24499517 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 17374